HR 8857 United States House · 119th Congress

Next GEN Act of 2026

The Next GEN Act of 2026 modifies the Drug Price Negotiation Program to include a specific category of medications called engineered cyclic peptides. This change extends the time before these drugs can be negotiated for lower prices from seven years to eleven years. The bill defines these peptides as synthetic, amino acid-based drugs that are self-administered and created using genetic library screening methods. By adjusting the timeline, the legislation directly affects pharmaceutical companies and the government agencies responsible for setting drug prices under the program.
Bill status in committee 1 of 4 stages cleared
Introduction
May 2026
Committee Review
Floor Vote
President
Introduced May 15, 2026 Last action May 15, 2026
Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
2
Key actions
0
Committee
1
May 15, 2026
Committee
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
lower
May 15, 2026
Introduced
Introduced in House
lower
1 primary · 4 co-sponsors

Sponsors